Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cidara Therapeutics, Inc. (CDTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.4613+0.0169 (+3.80%)
At close: 04:00PM EDT
0.4799 +0.02 (+4.03%)
After hours: 07:57PM EDT
Advertisement
Sign in to post a message.
  • G
    Georgio
    CDTX is a sleeper that will awaken 2022 good pipeline in the works and FDA approval and $5+ coming soon 2022. and possible buyout from Janessen pharms collaboration. CDTX is still rated Buy from several reputable analysts.......I buying at this level.
  • J
    Jayson
    CDTX 1st. Qtr. 2022 are looking pretty decent Revenues way up and earnings have taking a turn for the better too. I bought more shares today it's going to survive and thrive. Good pipeline is getting bigger. $5+ in 2022 is not out of the question. CDTX is a promising investment
    Bullish
  • B
    Bruno
    HC Wainwright lowered the price target to $6 from $7.50, citing the challenging capital market environment.

    Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock
    https://finance.yahoo.com/news/read-why-hc-wainwright-lowered-193639951.html

    May 12, 2022
  • n
    noe
    Are we going up to $1?
    Anybody?
    Bullish
  • T
    THOMAS
    this company need to be acquired that is the only thing that would make sense
  • J
    Jayson
    Good news today for CDTX holders
    Bullish
  • E
    EAR
    Who us buying? why no insider buys?
  • G
    Georgio
    CDTX has had some Strong Buy/buy ratings for awhile this good news this week seems to justify ratings now CDTX is worth buying & holding onto at these prices.
  • G
    Georgio
    This little stock is full of potential CDTX good stuff in it's pipeline good news with FDA final approval could push $5+ eventually. I see back over $1 or $2 soon. buying & holding this one.
  • M
    M_R..CA
    is there any news
  • G
    Georgio
    Some Good news is coming out. Volume and Share price going higher looke the back over $1? Wowee zowee
    CDTX shares 47% owned by Big Funds. CDTX has had new drug approved recently and has others doing good in trials right now. This one has alot of potential growth 2022 Buy and Hold investment here
  • L
    Luca
    Monday we shall see how the stock fares after the presentations in Lisbon
  • J
    Jayson
    I beieve this little CDTX has the ability to go much higher, why? because the have some good new anti-fungal drugs in their pipeline that passed phase 3 trials and more coming. Buy&Hold this one.
  • Y
    Yahoo Finance Insights
    Cidara Therapeutics is up 10.33% to 0.78
  • A
    Anonymous
    FiH CD388: check!
  • A
    Archimedes
    Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis

    Check the YF Summary tab... GLTA!
    Bullish
  • G
    G$
    This just had the exact same market response as another successful anti-fungal company (SCYX). In the case of Scynexis, they were granted full FDA approval. Stock price tanked and is still trying to recover. This theme is playing out across the biotech space all year. Great news, stock drops. It certainly feels like Wall Street is focused on depressing this sector. I'm invested in multiple bio's that have achieved big milestones and all have low to no debt, cash in hand and otherwise should be promising investments that have the potential for large gains, but all of them are in the red and no one has any insights on why. I have only one recourse which is to hold and wait for Wall Street to decide to start pumping $$ back into the sector.
  • S
    Shlomo
    (CDTX) Market Cap $74 million / Cash balance $75 million / Big Phase 3 readout by next Quarter / has Dealswith big Pharma like Mundipharma & Janssen worth $1.3 BILLION =MASSIVE underpriced stock with huge upside .More informations see below :

    Upcoming milestones
    https://assets.wallstreet-online.de/_media/8763/board/20210802135429-screenshot-2021-08-02-at-13-45-09-powerpoint-pres.png

    Presentation (July)
    https://ir.cidara.com/static-files/2e04fdaf-6edd-47e8-8644-78ee106eb3b6
  • m
    mark
    7 million trades and they expect shareholders to believe its all sell orders. possible, but manipulation is more likely. in for 15,500 shares.
  • J
    J
    Why's this stock at $1.60 if it's waiting on Phase 3 data? Either is woefully undervalued or just a lemon. Hopefully it's the former.
Advertisement
Advertisement